Seeking Alpha

Geron (GERN) shares +7.8% to $2.59 after Stifel Nicolas initiates the biotech company with a...

Geron (GERN) shares +7.8% to $2.59 after Stifel Nicolas initiates the biotech company with a "buy" rating and gives it a price target of $4. The rating adds to the positive buzz surrounding Geron - a Seeking Alpha article earlier this month said the firm's drugs "have the potential to change the way cancer is treated."
Comments (2)
  • Gainz Burger
    , contributor
    Comments (17) | Send Message
     
    This stock was left for dead and in hibernation for the past year- nice to see it re-animated and getting upgrades. Immetelstat could be a game changer. Successful phase II trials will send this well past $4
    30 Aug 2012, 10:30 AM Reply Like
  • jbl898
    , contributor
    Comments (8) | Send Message
     
    I agree.I believe the stock will go well past 4.
    30 Aug 2012, 04:48 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs